We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+8.48%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.8B
AUM Growth
+$629M
Cap. Flow
-$312M
Cap. Flow %
-2.1%
Top 10 Hldgs %
24.14%
Holding
917
New
50
Increased
256
Reduced
457
Closed
57

Top Buys

Rank Stock Value
1
VERU icon
Veru
VERU
+$53M
2
MELI icon
Mercado Libre
MELI
+$43.2M
3
DAR icon
Darling Ingredients
DAR
+$41.7M
4
JNJ icon
Johnson & Johnson
JNJ
+$33.7M
5
MET icon
MetLife
MET
+$31.1M

Top Sells

Rank Stock Value
1
PEP icon
PepsiCo
PEP
+$46.1M
2
NKE icon
Nike
NKE
+$36.6M
3
ITW icon
Illinois Tool Works
ITW
+$35.8M
4
AAPL icon
Apple
AAPL
+$31.9M
5
GILD icon
Gilead Sciences
GILD
+$29.8M

Sector Composition

Rank Sector Weight
1 Healthcare 33.32%
2 Technology 22.84%
3 Financials 10.04%
4 Consumer Discretionary 7.69%
5 Industrials 7.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EHC icon
676
Encompass Health
EHC
$11.5B
$937K 0.01%
15,660
-4,247
-21% -$231K
PHAT icon
677
Phathom Pharmaceuticals
PHAT
$930M
$935K 0.01%
83,357
-28,678
-26% -$296K
SGFY
678
DELISTED
Signify Health, Inc.
SGFY
$934K 0.01%
32,601
– –
TBPH icon
679
Theravance Biopharma
TBPH
$875M
$933K 0.01%
83,202
-19,626
-19% -$206K
AVIR icon
680
Atea Pharmaceuticals
AVIR
$361M
$933K 0.01%
193,956
+64,627
+50% +$327K
BRO icon
681
Brown & Brown
BRO
$25B
$924K 0.01%
+16,227
New +$949K
ACRS icon
682
Aclaris Therapeutics
ACRS
$744M
$924K 0.01%
58,647
+2,368
+4% +$38.1K
LGND icon
683
Ligand Pharmaceuticals
LGND
$5.94B
$905K 0.01%
+13,546
New +$881K
ALEC icon
684
Alector
ALEC
$169M
$904K 0.01%
97,938
+5,825
+6% +$50.8K
VREX icon
685
Varex Imaging
VREX
$469M
$902K 0.01%
44,424
-432
-1% -$9.04K
ALV icon
686
Autoliv
ALV
$9.09B
$900K 0.01%
11,758
-5,420
-32% -$433K
CNQ icon
687
Canadian Natural Resources
CNQ
$92.2B
$899K 0.01%
32,410
– –
MMSI icon
688
Merit Medical Systems
MMSI
$4.67B
$886K 0.01%
12,544
-4,183
-25% -$279K
ENB icon
689
Enbridge
ENB
$121B
$886K 0.01%
22,679
-4,714
-17% -$184K
CSTL icon
690
Castle Biosciences
CSTL
$725M
$885K 0.01%
37,595
+3,172
+9% +$73.5K
KIM icon
691
Kimco Realty
KIM
$17.7B
$883K 0.01%
41,712
-9,142
-18% -$192K
ENOV icon
692
Enovis
ENOV
$1.7B
$879K 0.01%
16,428
-3,239
-16% -$167K
TDY icon
693
Teledyne Technologies
TDY
$30.1B
$879K 0.01%
2,198
– –
PDCO
694
DELISTED
Patterson Companies, Inc.
PDCO
$874K 0.01%
31,182
-6,826
-18% -$188K
BG icon
695
Bunge Global
BG
$22.8B
$871K 0.01%
8,730
-12,560
-59% -$1.21M
CPT icon
696
Camden Property Trust
CPT
$11.4B
$866K 0.01%
7,744
-1,502
-16% -$172K
SENS icon
697
Senseonics Holdings Inc
SENS
$256M
$865K 0.01%
41,993
+12,796
+44% +$295K
MLAB icon
698
Mesa Laboratories
MLAB
$559M
$856K 0.01%
5,150
-726
-12% -$114K
ADPT icon
699
Adaptive Biotechnologies
ADPT
$3.6B
$856K 0.01%
111,982
+1,489
+1% +$11.6K
HSIC icon
700
Henry Schein
HSIC
$9.76B
$854K 0.01%
10,688
-2,180
-17% -$165K
26 27
28
29 30

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q4 2022 Portfolio in Review

As of Q4 2022, Candriam SCA held 917 positions worth $14.8B, up 4.4% from $14.2B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Candriam SCA's Q4 2022 filing shows 50 new, 256 increased, 457 reduced and 57 closed positions. Its largest new stake was Sarepta Therapeutics: 95,144 shares worth $12.3M. The largest sale was PepsiCo, an estimated $46.1M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 32% a quarter earlier, followed by Technology and Financials.

  • Candriam SCA's largest Q4 2022 buy was Sarepta Therapeutics: 95,144 shares worth $12.3M.
  • Candriam SCA added most to Veru in Q4 2022, an estimated $53M increase.
  • Candriam SCA's biggest Q4 2022 reduction was PepsiCo, cutting an estimated $46.1M.
  • Candriam SCA fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $24.6M.
  • Candriam SCA's ten largest holdings make up 24% of its $14.8B portfolio in Q4 2022.
  • Candriam SCA opened 50 new positions and closed 57 in Q4 2022.
  • Candriam SCA's portfolio value rose 4.4% quarter-over-quarter to $14.8B.

Based on Candriam SCA's 13F filing for Q4 2022, filed 13 Feb 2023.